Arzu Aysan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arzu Aysan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Hüseyin Balcı
Gebze Technical University
5 shared publications - Tuğçe Deniz Karaca
Gazi University
4 shared publications - Yusuf Sert
Bozok Üniversitesi
3 shared publications - Elif Şenkuytu
Department of Chemistry, Faculty of Science Atatürk University Erzurum Turkey
2 shared publications - Tamer Yagci
Department of Molecular Biology and Genetics , 52962 Gebze Technical University , Gebze , Kocaeli , Türkiye
2 shared publications - Alev Doğan
Faculty of Gazi Education, Gazi University
1 shared publication
Latest Publications
- 18 October 2026
- Published by Wiley in Biotechnology and Bioengineering
Engineering 4‐Vinylcatechol Biosynthesis in Escherichia coli Through Host–Enzyme Combination
De novo biosynthesis of 4‐vinylcatechol (VCAT), a valuable bio‐based monomer and potent antioxidant, has emerged as a crucial objective due to its profound industrial and pharmacological significance. However, its biosynthesis is frequently hindered by limited precursor availability. In this study, we developed a highly efficient, dual‐plasmid platform utilizing engineered Escherichia coli cell factories to synthesize VCAT directly from glucose without precursor feeding. To establish optimal production cells, we evaluated combinations of different host strains and phenolic acid decarboxylase ( PAD ) sources. Our results indicate that BL21(DE3) is less suitable for efficient de novo VCAT biosynthesis under the conditions tested. In contrast, the rpoA14(DE3), featuring a reprogrammed shikimate pathway, provided a more favorable host for VCAT production and enabled endogenous tyrosine supply, thereby eliminating the need for exogenous tyrosine supplementation required in BL21(DE3). To maximize this enhanced intracellular flux, we comparatively evaluated padC genes from different Bacillus subtilis strains. Comparative analysis demonstrated that the rpoA14(DE3)‐10A5 exhibited significantly superior production titers, markedly outperforming both its 168‐PAD counterpart and the standard BL21(DE3) expression hosts. Cultivated in single‐step, aqueous fermentation at mild conditions, this optimal host–enzyme combination achieved de novo accumulation of 200 mg/L VCAT, promising scalable biosynthesis.
- 18 October 2026
- Published by Wiley in Biotechnology and Bioengineering
Engineering 4‐Vinylcatechol Biosynthesis in Escherichia coli Through Host–Enzyme Combination
De novo biosynthesis of 4‐vinylcatechol (VCAT), a valuable bio‐based monomer and potent antioxidant, has emerged as a crucial objective due to its profound industrial and pharmacological significance. However, its biosynthesis is frequently hindered by limited precursor availability. In this study, we developed a highly efficient, dual‐plasmid platform utilizing engineered Escherichia coli cell factories to synthesize VCAT directly from glucose without precursor feeding. To establish optimal production cells, we evaluated combinations of different host strains and phenolic acid decarboxylase ( PAD ) sources. Our results indicate that BL21(DE3) is less suitable for efficient de novo VCAT biosynthesis under the conditions tested. In contrast, the rpoA14(DE3), featuring a reprogrammed shikimate pathway, provided a more favorable host for VCAT production and enabled endogenous tyrosine supply, thereby eliminating the need for exogenous tyrosine supplementation required in BL21(DE3). To maximize this enhanced intracellular flux, we comparatively evaluated padC genes from different Bacillus subtilis strains. Comparative analysis demonstrated that the rpoA14(DE3)‐10A5 exhibited significantly superior production titers, markedly outperforming both its 168‐PAD counterpart and the standard BL21(DE3) expression hosts. Cultivated in single‐step, aqueous fermentation at mild conditions, this optimal host–enzyme combination achieved de novo accumulation of 200 mg/L VCAT, promising scalable biosynthesis.
- Open Access
- 14 August 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 50 (4) , 306-320
Discovery and functional characterization of novel programmed death-ligand 1 monoclonal antibodies
Background/aim: Targeted therapies with monoclonal antibodies provide cancer patients with better prognosis and diseasefree survival. The blockade of immune checkpoints, including programmed cell death protein-1 (PD-1) and its ligand PD-L1, with monoclonal antibodies may boost immune responses against tumors and is regarded as an effective strategy in cancer immunotherapy. We describe the generation of anti-PD-L1 monoclonal antibodies with high affinity and specificity, and we assess their potential for therapeutic use in cancer. Materials and methods: Hybridomas were selected for PD-L1 specificity and cross-reactivity with other immune checkpoint proteins and PD-L1 orthologs using indirect ELISA. Immunofluorescence and Western blotting assays were conducted for further characterization of the antibodies. The affinities of the antibodies for PD-L1 were determined using surface plasmon resonance. Receptor blocking activities were examined through competitive ELISA and cell-based luciferase reporter assays. Sequences of variable regions of the selected antibodies were determined by Sanger sequencing and subjected to BLAST analysis. Results: A total of 25 PD-L1-specific monoclonal antibodies were generated. While most clones reacted with PD-L1 from cynomolgus monkeys, none of the antibodies displayed cross-reactivity with other checkpoint proteins. Immunofluorescence assays showed that the selected clones stained PD-L1-expressing cell membranes specifically, but not those of PD-L1-negative cells. Western blotting revealed that most of the clones recognized both glycosylated and nonglycosylated PD-L1, and a few reacted with the glycosylated form only. Only two clones with subnanomolar affinity for human PD-L1 were effective at blocking PD-1/PD-L1 and CD80/PD-L1 interactions. Sequence analysis of their variable regions revealed their unique specificity. Conclusion: Of the 25 monoclonal antibodies produced in this study, only one was identified as a potential therapeutic drug candidate thanks to its high capacity for checkpoint blockade and affinity, as well as its unique sequence specificity. These properties are comparable to those of anti-PD-L1 antibodies currently used in clinical practice.
- 14 August 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 50 (4) , 306-320
Open AccessDiscovery and functional characterization of novel programmed death-ligand 1 monoclonal antibodies
Background/aim: Targeted therapies with monoclonal antibodies provide cancer patients with better prognosis and diseasefree survival. The blockade of immune checkpoints, including programmed cell death protein-1 (PD-1) and its ligand PD-L1, with monoclonal antibodies may boost immune responses against tumors and is regarded as an effective strategy in cancer immunotherapy. We describe the generation of anti-PD-L1 monoclonal antibodies with high affinity and specificity, and we assess their potential for therapeutic use in cancer. Materials and methods: Hybridomas were selected for PD-L1 specificity and cross-reactivity with other immune checkpoint proteins and PD-L1 orthologs using indirect ELISA. Immunofluorescence and Western blotting assays were conducted for further characterization of the antibodies. The affinities of the antibodies for PD-L1 were determined using surface plasmon resonance. Receptor blocking activities were examined through competitive ELISA and cell-based luciferase reporter assays. Sequences of variable regions of the selected antibodies were determined by Sanger sequencing and subjected to BLAST analysis. Results: A total of 25 PD-L1-specific monoclonal antibodies were generated. While most clones reacted with PD-L1 from cynomolgus monkeys, none of the antibodies displayed cross-reactivity with other checkpoint proteins. Immunofluorescence assays showed that the selected clones stained PD-L1-expressing cell membranes specifically, but not those of PD-L1-negative cells. Western blotting revealed that most of the clones recognized both glycosylated and nonglycosylated PD-L1, and a few reacted with the glycosylated form only. Only two clones with subnanomolar affinity for human PD-L1 were effective at blocking PD-1/PD-L1 and CD80/PD-L1 interactions. Sequence analysis of their variable regions revealed their unique specificity. Conclusion: Of the 25 monoclonal antibodies produced in this study, only one was identified as a potential therapeutic drug candidate thanks to its high capacity for checkpoint blockade and affinity, as well as its unique sequence specificity. These properties are comparable to those of anti-PD-L1 antibodies currently used in clinical practice.
- 5 January 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (1) , e70229
Novel Benzimidazole‐Urea Phenylalanine Hybrids as Dual‐Acting Antimicrobial and Anticancer Agents: In Silico and Biological Evaluation
The emergence of multidrug‐resistant microorganisms and the limited therapeutic options for hepatocellular carcinoma (HCC) highlight the urgent need for new molecular scaffolds with dual pharmacological potential. In this study, a novel series of benzimidazole‐urea phenylalanine hybrids was designed and synthesized using a rational structure‐based approach to integrate antimicrobial and anticancer functionalities within a single pharmacophore. All synthesized compounds were characterized by spectroscopic methods and evaluated for their antimicrobial and cytotoxic activities. Among the series, CPN305 exhibited the most potent cytotoxicity against hepatocellular carcinoma cell lines (PLC/PRF/5 and HuH7) while maintaining minimal toxicity toward normal human fibroblasts (BJ‐1). Additionally, the compound demonstrated promising antimicrobial efficacy against Staphylococcus aureus . Molecular docking simulations revealed favorable binding interactions within the Hsp90 active site, supporting the observed in vitro anticancer effects, while ADME predictions indicated desirable physicochemical and pharmacokinetic properties. Collectively, these findings suggest that the benzimidazole‐urea phenylalanine scaffold represents a promising lead framework for further structural optimization and mechanistic exploration as a dual‐acting antimicrobial and anticancer agent.
- 5 January 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (1) , e70229
Novel Benzimidazole‐Urea Phenylalanine Hybrids as Dual‐Acting Antimicrobial and Anticancer Agents: In Silico and Biological Evaluation
The emergence of multidrug‐resistant microorganisms and the limited therapeutic options for hepatocellular carcinoma (HCC) highlight the urgent need for new molecular scaffolds with dual pharmacological potential. In this study, a novel series of benzimidazole‐urea phenylalanine hybrids was designed and synthesized using a rational structure‐based approach to integrate antimicrobial and anticancer functionalities within a single pharmacophore. All synthesized compounds were characterized by spectroscopic methods and evaluated for their antimicrobial and cytotoxic activities. Among the series, CPN305 exhibited the most potent cytotoxicity against hepatocellular carcinoma cell lines (PLC/PRF/5 and HuH7) while maintaining minimal toxicity toward normal human fibroblasts (BJ‐1). Additionally, the compound demonstrated promising antimicrobial efficacy against Staphylococcus aureus . Molecular docking simulations revealed favorable binding interactions within the Hsp90 active site, supporting the observed in vitro anticancer effects, while ADME predictions indicated desirable physicochemical and pharmacokinetic properties. Collectively, these findings suggest that the benzimidazole‐urea phenylalanine scaffold represents a promising lead framework for further structural optimization and mechanistic exploration as a dual‐acting antimicrobial and anticancer agent.
- Open Access
- 23 November 2025
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Evaluation of the antimicrobial-cytotoxic activities and molecular docking study of L-cysteine ethyl ester and L-cysteine methyl ester
Antibiotic resistance is a growing problem in the treatment of life-threatening diseases. Recently, a variety of covalent drugs have emerged. Cysteine is one of the least abundant amino acids in the proteins of many organisms, and the thiol group in its structure makes it unique and has become a common covalent amino acid residue in covalent drug development. Therefore, it is important to conduct research on cysteine derivatives. In this study, the in vitro antibacterial activity of L-cysteine esters were tested against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli using the modified microdilution broth method. In vitro cytotoxic activities of the esters were carried out against the healthy HEK293T cell line and well-differentiated liver cancer cell lines PLC/PRF/5 and HEP3B at different concentrations by using an MTS assay. In addition, molecular docking studies, ADMET properties, and drug-likeness were also reported. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable cysteine-based drugs. In conclusion, a thorough examination of the frontier orbital (HOMO and LUMO) and MEP studies was conducted using quantum chemistry techniques to determine the molecule’s reactivity, electrophilic and nucleophilic sites.
- 23 November 2025
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Open AccessEvaluation of the antimicrobial-cytotoxic activities and molecular docking study of L-cysteine ethyl ester and L-cysteine methyl ester
Antibiotic resistance is a growing problem in the treatment of life-threatening diseases. Recently, a variety of covalent drugs have emerged. Cysteine is one of the least abundant amino acids in the proteins of many organisms, and the thiol group in its structure makes it unique and has become a common covalent amino acid residue in covalent drug development. Therefore, it is important to conduct research on cysteine derivatives. In this study, the in vitro antibacterial activity of L-cysteine esters were tested against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli using the modified microdilution broth method. In vitro cytotoxic activities of the esters were carried out against the healthy HEK293T cell line and well-differentiated liver cancer cell lines PLC/PRF/5 and HEP3B at different concentrations by using an MTS assay. In addition, molecular docking studies, ADMET properties, and drug-likeness were also reported. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable cysteine-based drugs. In conclusion, a thorough examination of the frontier orbital (HOMO and LUMO) and MEP studies was conducted using quantum chemistry techniques to determine the molecule’s reactivity, electrophilic and nucleophilic sites.
- 1 October 2025
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 53 (4) , 33-46
Analyses and Comparisons of the Antimicrobial-Cytotoxic Effects and Molecular Docking Study of L-DOPA and L-DOPA Methyl Ester
The increasing the importance of synthesizing compounds with high biocompatibility, low cytotoxicity, and advanced antibacterial properties is evident in current research. L-3,4-Dihydroxyphenylalanine (L-DOPA) is a crucial drug widely used in the treatment of Parkinson's disease. In this study, we investigated the antimicrobial and cytotoxic effects of L-DOPA and its water-soluble derivative, L-DOPA methyl ester. The antimicrobial effects of L-DOPA and L-DOPA Methyl Ester were tested on both Gram-negative and Gram-positive bacteria. Additionally, the impact of L-DOPA and its ester on cell viability was assessed using the MTT assay on cancerous and non-cancerous cell lines. The study revealed that both substances were effective against Gram-positive bacteria but not Gram-negative bacteria. Specifically, the growth of Gram-positive bacteria was inhibited by both compounds, with L-DOPA showing greater efficacy. We also observed that L-DOPA and its ester exhibit anti-cancer activity. Furthermore, the molecular docking mechanism between the three targets (2DS2, 4URO and 1M17) and the compounds was investigated using Autodock Vina. The findings show that the L-DOPA molecule is more appropriately attached to the target receptors than the L-DOPA methyl ester molecule. As a result, its inhibition is greater. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable drug studies.
- 1 October 2025
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 53 (4) , 33-46
Analyses and Comparisons of the Antimicrobial-Cytotoxic Effects and Molecular Docking Study of L-DOPA and L-DOPA Methyl Ester
The increasing the importance of synthesizing compounds with high biocompatibility, low cytotoxicity, and advanced antibacterial properties is evident in current research. L-3,4-Dihydroxyphenylalanine (L-DOPA) is a crucial drug widely used in the treatment of Parkinson's disease. In this study, we investigated the antimicrobial and cytotoxic effects of L-DOPA and its water-soluble derivative, L-DOPA methyl ester. The antimicrobial effects of L-DOPA and L-DOPA Methyl Ester were tested on both Gram-negative and Gram-positive bacteria. Additionally, the impact of L-DOPA and its ester on cell viability was assessed using the MTT assay on cancerous and non-cancerous cell lines. The study revealed that both substances were effective against Gram-positive bacteria but not Gram-negative bacteria. Specifically, the growth of Gram-positive bacteria was inhibited by both compounds, with L-DOPA showing greater efficacy. We also observed that L-DOPA and its ester exhibit anti-cancer activity. Furthermore, the molecular docking mechanism between the three targets (2DS2, 4URO and 1M17) and the compounds was investigated using Autodock Vina. The findings show that the L-DOPA molecule is more appropriately attached to the target receptors than the L-DOPA methyl ester molecule. As a result, its inhibition is greater. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable drug studies.
- Open Access
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 219-232
Knockdown of Plexin C1 induces epithelial-to-mesenchymal transition and confers resistance to multikinase inhibitors in hepatocellular carcinoma cells
Background/aim: HCC is a common and lethal malignancy and multi-kinase inhibitors (MKIs) are among the therapeutic options for unresectable cases. However, response rates to MKIs remained variable, necessitating the identification of predictive biomarkers. Plexin C1 (PLXNC1), a receptor involved in cell signaling, has emerged as a potential candidate to regulate tumor responses. This study aims to evaluate the impact of PLXNC1 expression on the sensitivity of HCC cells to MKI therapy. Materials and methods: shRNA-mediated PLXNC1 knock-down and control clones of HCC cell lines PLC/PRF/5 and Hep3B were generated, and downregulation of PLXNC1 was confirmed using Western blotting. The effects of MKIs sorafenib and lenvatinib on apoptotic cell death and proliferation of HCC cell clones were explored in relation to PLXNC1 expression. Furthermore, tumor responses to MKIs were evaluated in mouse xenograft models engrafted with shPLXNC1 and control clones of PLC/PRF/5 cells. Results: The results of our in vitro studies indicate that PLXNC1 expression is linked to heightened sensitivity of HCC cells to MKIs. Furthermore, the knockdown of PLXNC1 in these cells resulted in a reduction in proliferation and an increase in apoptosis resistance. The findings were validated in hepatocellular carcinoma (HCC) tumor models in immunodeficient mice, which revealed that cells expressing PLXNC1 were responsive to drug treatment. In PLXNC1-silenced cells, tumor volumes remained stationary, which was attributable to the antiproliferative effect of PLXNC1 knockdown. Conclusion: PLXNC1 expression may serve as a predictive biomarker for MKI efficacy in HCC and provides a potential avenue for personalized therapeutic strategies. Further clinical validation is required to incorporate PLXNC1 into routine diagnostic and treatment protocols for HCC.
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 219-232
Open AccessKnockdown of Plexin C1 induces epithelial-to-mesenchymal transition and confers resistance to multikinase inhibitors in hepatocellular carcinoma cells
Background/aim: HCC is a common and lethal malignancy and multi-kinase inhibitors (MKIs) are among the therapeutic options for unresectable cases. However, response rates to MKIs remained variable, necessitating the identification of predictive biomarkers. Plexin C1 (PLXNC1), a receptor involved in cell signaling, has emerged as a potential candidate to regulate tumor responses. This study aims to evaluate the impact of PLXNC1 expression on the sensitivity of HCC cells to MKI therapy. Materials and methods: shRNA-mediated PLXNC1 knock-down and control clones of HCC cell lines PLC/PRF/5 and Hep3B were generated, and downregulation of PLXNC1 was confirmed using Western blotting. The effects of MKIs sorafenib and lenvatinib on apoptotic cell death and proliferation of HCC cell clones were explored in relation to PLXNC1 expression. Furthermore, tumor responses to MKIs were evaluated in mouse xenograft models engrafted with shPLXNC1 and control clones of PLC/PRF/5 cells. Results: The results of our in vitro studies indicate that PLXNC1 expression is linked to heightened sensitivity of HCC cells to MKIs. Furthermore, the knockdown of PLXNC1 in these cells resulted in a reduction in proliferation and an increase in apoptosis resistance. The findings were validated in hepatocellular carcinoma (HCC) tumor models in immunodeficient mice, which revealed that cells expressing PLXNC1 were responsive to drug treatment. In PLXNC1-silenced cells, tumor volumes remained stationary, which was attributable to the antiproliferative effect of PLXNC1 knockdown. Conclusion: PLXNC1 expression may serve as a predictive biomarker for MKI efficacy in HCC and provides a potential avenue for personalized therapeutic strategies. Further clinical validation is required to incorporate PLXNC1 into routine diagnostic and treatment protocols for HCC.
- Open Access
- 15 August 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (8) , 881-889
SIX1 Downregulation Suppresses Self-renewal Capacity and THY1 Expression in Hepatocellular Carcinoma and SIX1 Dominate the Survival in Liver Cancer
Background/Aims: Sine oculis homeoprotein 1 exerts an essential role in embryonic development, and it was also identified to be reactivated in various types of mammalian cancer. The sine oculis homeoprotein 1 transcription factor was demonstrated to induce epithelial–mesenchymal transition, regulate crucial genes associated with cancer progression, and increase the oncogenic potential of cells. Therefore, the present study aimed to identify the role of sine oculis homeoprotein 1 in cancer. Materials and Methods: Sine oculis homeoprotein 1 gene expression was tested with real-time quantitative polymerase chain reaction (PCR) in different cancer types. Sine oculis homeoprotein 1 expression was suppressed by short hairpin RNA transduction in the SNU398 hepatocellular carcinoma cell line. The effects of sine oculis homeoprotein 1 on cell proliferation, drug resistance, and sphere formation were assessed in shSIX1 cells. Immunohistochemical and in silico analyses were performed to determine the prognostic role of sine oculis homeoprotein 1 expression. Results: The upregulated expression levels of sine oculis homeoprotein 1 were revealed to be correlated with the stage of the disease in breast, colon, and liver cancer, with liver cancer exhibiting the highest expression profile. Sine oculis homeoprotein 1 downregulation significantly affected cell proliferation and suppressed sorafenib resistance and sphere-forming ability. Furthermore, sine oculis homeoprotein 1 knockdown cells were identified to have decreased CD90 levels, essential for cancer stem cell properties. Finally, sine oculis homeoprotein 1 expression was a CD90-independent biomarker for the clinical prognosis of liver cancer. Conclusion: The results of this study showed that the knockdown of sine oculis homeoprotein 1 expression might help to prevent hepatocarcinogenesis by increasing drug sensitivity and controlling tumor sphere formation. Overall, these results indicated that sine oculis homeoprotein 1 expression might be useful as a diagnostic marker for patients with hepatocellular carcinoma. Cite this article as: Balçık-Erçin P, Aysan A, Salık N, Erciyas E. SIX1 downregulation suppresses self-renewal capacity and THY1 expression in hepatocellular carcinoma and SIX1 dominate the survival in liver cancer. Turk J Gastroenterol. 2023;34(8):881-889.
- 15 August 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (8) , 881-889
Open AccessSIX1 Downregulation Suppresses Self-renewal Capacity and THY1 Expression in Hepatocellular Carcinoma and SIX1 Dominate the Survival in Liver Cancer
Background/Aims: Sine oculis homeoprotein 1 exerts an essential role in embryonic development, and it was also identified to be reactivated in various types of mammalian cancer. The sine oculis homeoprotein 1 transcription factor was demonstrated to induce epithelial–mesenchymal transition, regulate crucial genes associated with cancer progression, and increase the oncogenic potential of cells. Therefore, the present study aimed to identify the role of sine oculis homeoprotein 1 in cancer. Materials and Methods: Sine oculis homeoprotein 1 gene expression was tested with real-time quantitative polymerase chain reaction (PCR) in different cancer types. Sine oculis homeoprotein 1 expression was suppressed by short hairpin RNA transduction in the SNU398 hepatocellular carcinoma cell line. The effects of sine oculis homeoprotein 1 on cell proliferation, drug resistance, and sphere formation were assessed in shSIX1 cells. Immunohistochemical and in silico analyses were performed to determine the prognostic role of sine oculis homeoprotein 1 expression. Results: The upregulated expression levels of sine oculis homeoprotein 1 were revealed to be correlated with the stage of the disease in breast, colon, and liver cancer, with liver cancer exhibiting the highest expression profile. Sine oculis homeoprotein 1 downregulation significantly affected cell proliferation and suppressed sorafenib resistance and sphere-forming ability. Furthermore, sine oculis homeoprotein 1 knockdown cells were identified to have decreased CD90 levels, essential for cancer stem cell properties. Finally, sine oculis homeoprotein 1 expression was a CD90-independent biomarker for the clinical prognosis of liver cancer. Conclusion: The results of this study showed that the knockdown of sine oculis homeoprotein 1 expression might help to prevent hepatocarcinogenesis by increasing drug sensitivity and controlling tumor sphere formation. Overall, these results indicated that sine oculis homeoprotein 1 expression might be useful as a diagnostic marker for patients with hepatocellular carcinoma. Cite this article as: Balçık-Erçin P, Aysan A, Salık N, Erciyas E. SIX1 downregulation suppresses self-renewal capacity and THY1 expression in hepatocellular carcinoma and SIX1 dominate the survival in liver cancer. Turk J Gastroenterol. 2023;34(8):881-889.
- Open Access
- 1 April 2023
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 51 (2) , 133-140
EVALUATION AND COMPARISON OF THE ANTIMICROBIAL AND CYTOTOXIC ACTIVITIES OF SOME AMINO ACID METHYL ESTERS
In this study, the antibacterial and cytotoxic activities of some amino acid methyl esters (L-methionine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, and L-tyrosine) were investigated. The effect of amino acid methyl ester compounds on antibacterial performance was determinated against Gram-negative and Gram-positive bacteria. The effect of amino acid esters on cell viability was investigated against cancerous and non-cancerous cell lines using the MTS assay. The results showed the substances had low antimicrobial effect on both Gram-negative and Gram-positive bacteria. In addition, it was found that the studied substances did not have a toxic effect on cell growth in non-cancerous cells. For this reason, it is thought that the results obtained will contribute to research on new synthesizable compounds based on amino acid esters and studies on drug development.
- 1 April 2023
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 51 (2) , 133-140
Open AccessEVALUATION AND COMPARISON OF THE ANTIMICROBIAL AND CYTOTOXIC ACTIVITIES OF SOME AMINO ACID METHYL ESTERS
In this study, the antibacterial and cytotoxic activities of some amino acid methyl esters (L-methionine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, and L-tyrosine) were investigated. The effect of amino acid methyl ester compounds on antibacterial performance was determinated against Gram-negative and Gram-positive bacteria. The effect of amino acid esters on cell viability was investigated against cancerous and non-cancerous cell lines using the MTS assay. The results showed the substances had low antimicrobial effect on both Gram-negative and Gram-positive bacteria. In addition, it was found that the studied substances did not have a toxic effect on cell growth in non-cancerous cells. For this reason, it is thought that the results obtained will contribute to research on new synthesizable compounds based on amino acid esters and studies on drug development.